Compare AXT Inc (AXTI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AXT Inc vs Novartis AG — how do they compare? AXT Inc trades at $56.56 (market cap $3.77B), while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG is far larger — about 76.6× AXT Inc's market cap, and Novartis AG pays a 3.15% dividend while AXT Inc pays none. Which is the better fit depends on your goals.
| AXTI | NVS | |
|---|---|---|
Market Cap | $3.77B | $288.65B |
Sector | Technology | Health |
52-Week High | $140.83 | $168.62 |
52-Week Low | $1.92 | $113.50 |
Enterprise Value | $3.73B | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $50.46, down 11.8% in the past 24 hours, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improved margins. Recent news highlights strong AI-driven demand for indium phosphide substrates and a $100M+ backlog, but export delays and cash flow risks remain concerns. Analyst consensus is bullish with 7 buy ratings, but technical indicators suggest near-term pressure.
The stock faces near-term headwinds from weak cash flow and high valuations (P/S 27.84), but long-term growth potential exists if AI demand materializes and capacity expansion executes smoothly. Key risks include geopolitical tensions affecting exports and execution challenges in scaling production. Investors should weigh the bullish analyst outlook against persistent fundamental weaknesses and technical bearishness.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
